Barcelona Liver Bioservices announces partnership with BrudyLab

9 January, 2018

Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.

In the initial phase of the collaboration, BLB will investigate the effects and underlying mechanisms of Brudy-DHA in pre-clinical models of chronic liver disease.

For more information about the services and research developed by BLB please visit